These results are in line with the past studies; Szarek et al. reported that agents enhancing glycemic control in patients with T2DM and heart failure showed modest HbA1c reductions in the range of 0.5% to 1.0%, highlighting that the 1.3% reduction seen with insulin in our study is clinically meaningful [14]. This evidence concerns the gene INS and type 2 diabetes mellitus.